Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) -
Pipeline Review, H2 2013 report provides an overview of the indication’s
therapeutic pipeline. This report provides information on the therapeutic
development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete
with latest updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic development
for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). Mucopolysaccharidosis I
(MPS I) (Hurler Syndrome) - Pipeline Review, Half Year is built using data and
information sourced from report proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put
together by publisher team.
Scope
- A snapshot of the global therapeutic scenario for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome).
- A review of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Spanning over 47 pages, 20 Tables and 6
Figures “Mucopolysaccharidosis I (MPS I)
(Hurler Syndrome) - Pipeline Review, H2 2013” report provide Mucopolysaccharidosis
I (MPS I) (Hurler Syndrome) Overview, Therapeutics Development,
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Therapeutics under
Development by Companies, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) -
Pipeline Products Glance, Drug Profiles, Product Description, Appendix and the
report cover 5 companies - Athersys, Inc., OPKO Health, Inc., Amicus
Therapeutics, Inc., ReGenX Biosciences, LLC, ArmaGen Technologies, Inc.
Inquiry for more information
visit: http://www.marketresearchreports.com/global-markets-direct/mucopolysaccharidosis-i-mps-i-hurler-syndrome-pipeline-review-h2-2013
Find All Pharma and Healthcare Reports at:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.